NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Multimodal AOMs were associated with the highest preoperative weight loss among patients with high BMI undergoing bariatric surgery.

Dapiglutide, a novel GLP-1/GLP-2 receptor agonist, was associated with body weight reductions of up to 8.3% at 13 weeks for ...

The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like ...

The Delhi High Court on Wednesday directed the Central Drugs Standard Control Organisation (CDSCO) to decide, within 3 months ...

The PIL seeks a ban on the marketing and distribution of specific GLP-1 receptor agonist (RA) drugs, namely Semaglutide, ...

Discover a recent report that states that, although GLP-1 medicines are generally well tolerated, there have been cases of ...